Publications by authors named "Susan Lattimore"

Claim this Profile
F
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
Steven W Pipe, Wolfgang Miesbach, Michael Recht, Frank W G Leebeek, Nigel S Key, Susan Lattimore

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.
Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Susan U Lattimore

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Susan U Lattimore

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science.
Vanessa R Byams, Judith R Baker, Cindy Bailey, Nathan T Connell, Melissa S Creary, Susan Lattimore

Expert Rev Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Steven W Pipe, Frank W G Leebeek, Michael Recht, Nigel S Key, Giancarlo Castaman, Susan Lattimore

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders.
Leonard A Valentino, Judith R Baker, Regina Butler, Miguel Escobar, Neil Frick, Susan Lattimore

J Blood Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes.
Stacy E Croteau, Allison P Wheeler, Osman Khan, Kristina M Haley, Alexandra J Borst, Susan Lattimore

Res Pract Thromb Haemost· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Susan Lattimore

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding.
Anne D Rocheleau, Ayesha Khader, Anh T P Ngo, Colin Boehnlein, Cara McDavitt, Susan Lattimore

Pediatr Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events.
Dong-Wha Kang, Susan U Lattimore, Lawrence L Latour, Steven Warach

Arch Neurol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telephone assessment of stroke outcome is reliable.
José G Merino, Susan U Lattimore, Steven Warach

Stroke· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.
Susan Unipan Lattimore, Julio Chalela, Lisa Davis, Thomas DeGraba, Mustapha Ezzeddine

Stroke· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis